FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves

The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.  

Blueprint said the FDA lifted the partial hold on its Phase I/II study of BLU-222 • Source: Shutterstock

More from Anticancer

More from Therapy Areas